C-MER Eye Care Set to See Loss in 2023 Despite Holding 3309 in Year Prior.
March 30, 2023
Trending News ☀️
The company’s outlook for 2022 is disheartening, as the stock market has proved to be volatile and unpredictable in the past year. C-MER ($SEHK:03309) Eye Care Holdings has seen significant losses in share value and unfortunately is not projected to recover in 2022. The company’s financial difficulties have been further complicated by the ongoing pandemic and ongoing economic recession.
With health and safety considerations at the forefront of all businesses, C-MER Eye Care Holdings has been forced to take steps to mitigate their losses and maintain their profitability. It remains uncertain as to whether or not C-MER Eye Care Holdings will be able to recover in the coming year or if they will continue to see losses throughout 2022.
Share Price
Despite the largely positive media sentiment surrounding C-MER EYE CARE, the company is expected to see a loss in 2023 despite holding 3309 in the year prior. On Thursday, C-MER EYE CARE stock opened at HK$4.7 and closed at the same price, up by 0.6% from its prior closing price of 4.6. This slight increase in price suggests that investors remain optimistic that the company will be able to reverse its expected losses for 2023. However, the market and investors must wait to see what strategies the company puts into place to help them weather the upcoming financial year. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for C-mer Eye Care. More…
| Total Revenues | Net Income | Net Margin |
| 1.47k | 22.96 | 2.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for C-mer Eye Care. More…
| Operations | Investing | Financing |
| 153.82 | -338.37 | 382.71 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for C-mer Eye Care. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 2.89k | 901.52 | 1.49 |
Key Ratios Snapshot
Some of the financial key ratios for C-mer Eye Care are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 43.2% | -26.7% | 3.1% |
| FCF Margin | ROE | ROA |
| 3.1% | 1.8% | 1.0% |
Analysis
At GoodWhale, we have conducted an extensive analysis of C-MER EYE CARE’s financials. Our risk rating indicates that this is a medium risk investment when it comes to both financial and business aspects. After closely reviewing the income sheet and cashflow statement, GoodWhale has detected two distinct risk warnings that could affect the success of this investment. For more detailed information about these warnings, please register with us. We encourage potential investors to consider this data when assessing the overall risk associated with C-MER EYE CARE. We are confident that with the right research and strategy, this investment could provide great returns in the future. More…
Peers
In the ever-changing landscape of eye care, C-Mer Eye Care Holdings Ltd is facing stiff competition from a number of international and regional rivals. Companies such as Singapore Paincare Holdings Ltd, Topvision Eye Specialist Bhd, and MediClin AG all offer quality services in the sector and are vying for the same market share. With all of these companies competing for the same business, C-Mer Eye Care Holdings Ltd must remain vigilant to stay ahead of the competition.
– Singapore Paincare Holdings Ltd ($SGX:FRQ)
Singapore Paincare Holdings Ltd is a medical healthcare provider specializing in treatment and management of pain-related medical conditions. The company has a market capitalization of 38.62M as of 2023, indicating its size and strength in the industry. Its Return on Equity (ROE) of 13.23% indicates that the company is creating value for its shareholders. Its robust financial performance also implies that the company is managing its resources effectively and efficiently.
– Topvision Eye Specialist Bhd ($KLSE:03013)
Topvision Eye Specialist Bhd is a Malaysian healthcare company that specializes in providing eye care services. With a market cap of 191.7M as of 2023, the company is well-positioned to continue providing comprehensive and quality eye care services to the Malaysian population. Furthermore, the company’s return on equity (ROE) of 29.99% demonstrates its ability to generate profits for its shareholders and provides investors with a reliable source of income. Topvision is committed to providing the highest quality services to its patients and strives to maintain a strong financial position.
– MediClin AG ($BER:MED)
MediClin AG is a German healthcare company based in Baden-Württemberg, Germany. It specializes in providing comprehensive healthcare solutions, such as medical and nursing services, health insurance, and medical technology. The company has a market cap of 161.5M as of 2023, making it one of the largest healthcare providers in Germany. Its Return on Equity (ROE) of 6.43% is quite impressive, indicating that the company is able to generate a healthy return on its investments. This is likely due to the company’s solid reputation for providing quality healthcare services at an affordable cost.
Summary
C-MER Eye Care is a global healthcare provider that has been experiencing steady growth in recent years. Media sentiment surrounding C-MER Eye Care remains mostly positive, making it a desirable investment. Analysts cite the company’s advanced medical technology and experienced team as factors contributing to its success.
A diversified customer base across multiple countries also helps to ensure continued success for the company. With continued research and development, this company could remain a top investment for years to come.
Related Posts
Recent Posts
